Edesa Biotech (EDSA) to Announce Earnings on Monday

Edesa Biotech (NASDAQ:EDSA) is expected to announce its results after the market closes on Monday, August 10th. Analysts expect Edesa Biotech to announce earnings of ($0.4350) per share for the quarter.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.25). On average, analysts expect Edesa Biotech to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edesa Biotech Stock Performance

Shares of EDSA opened at $5.27 on Friday. The stock has a fifty day moving average price of $6.41 and a two-hundred day moving average price of $6.23. Edesa Biotech has a 52-week low of $0.72 and a 52-week high of $20.32. The company has a market cap of $50.77 million, a price-to-earnings ratio of -3.93 and a beta of 1.08.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Edesa Biotech in a research note on Wednesday, June 24th. Brookline Capital Markets upgraded shares of Edesa Biotech to a “strong-buy” rating in a research report on Monday, June 29th. Finally, Wall Street Zen lowered shares of Edesa Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EDSA. Diadema Partners LP acquired a new stake in shares of Edesa Biotech in the 4th quarter valued at $77,000. State Street Corp bought a new stake in shares of Edesa Biotech during the fourth quarter worth $27,000. DRW Securities LLC acquired a new position in shares of Edesa Biotech during the fourth quarter valued at $191,000. Finally, Susquehanna International Group LLP acquired a new position in shares of Edesa Biotech during the third quarter valued at $36,000. Institutional investors and hedge funds own 5.50% of the company’s stock.

Edesa Biotech Company Profile

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.